WHO downgrades oseltamivir on drugs list after reviewing evidence

  title={WHO downgrades oseltamivir on drugs list after reviewing evidence},
  author={Zosia Kmietowicz},
  journal={British Medical Journal},
Oseltamivir (Tamiflu) has been downgraded in the World Health Organization’s list of essential medicines from a “core” drug to one that is “complementary”—a category encompassing drugs that are deemed less cost effective. Fiona Godlee, The BMJ ’s editor in chief, welcomed the move as a victory for the journal’s campaign for evidence based medicine. “WHO’s decision is a vote for evidence based policy making, which will save money and harm. It is also … 
Treat suspected flu with antivirals, hospital doctors are told
Patients admitted to acute hospitals in England with suspected flu should be treated with antiviral drugs as quickly as possible, NHS trusts have been told in a letter from the national medicalExpand
Pseudoephedrine protects mice from infection of H1N1 virus
It is well known that the development in luenza vaccine is hysteretic generally, and some targeted drugs have been developed for treating in lUenza, such as Oseltamivir, but the effect is lower cost-effectiveness and moved out of the recommended list by WHO. Expand
Clinicians’ attitude towards a placebo-controlled randomised clinical trial investigating the effect of neuraminidase inhibitors in adults hospitalised with influenza
There is strong support from UK clinicians for a placebo-controlled trial of NAI treatment in adults hospitalised with suspected influenza, and low use of NAIs in the UK suggests randomisation of treatment would not substantially divert patients towards placebo. Expand
Effectiveness of Oseltamivir in reducing 30-day readmissions and mortality among patients with severe seasonal influenza in Australian hospitalised patients.
Early administration of Oseltamivir is associated with a reduction in 30-days readmission and composite-outcome of 30-day readmissions and mortality in adult hospitalised influenza patients when compared to delayed/no-treatment. Expand
Drugs for Influenza Treatment: Is There Significant News?
The clinical roles of antiviral drugs against influenza that have been licensed in at least one country and the potential roles of compounds that are in development are shown. Expand
Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection.
This study supports that, in daily practice, patients admitted with influenza virus infection should be treated with oseltamivir within 48 hours of admission, even if they have complaints for more than 48 hours. Expand
Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary CarE (ALIC4 E): the ALIC4 E protocol
The primary objective is to determine whether adding antiviral treatment to best usual primary care is effective in reducing time to return to usual daily activity with fever, headache and muscle ache reduced to minor severity or less. Expand
Clinical Practice Guideline on Treating Influenza in Adult Patients with Chinese Patent Medicines.
An evidence-based guideline on treating influenza with Chinese patent medicines in adults to guide clinical practice and recommends Lianhua Qingwen capsule in combination with antiviral medications and supportive therapy, which was weak. Expand
Evidencias para el diagnóstico y tratamiento de influenza en adultos
Treatment with antiviral therapy based on a neuraminidase inhibitor may shorten the duration of the symptoms, in addition to reducing the complications particularly in immunocompromised individuals or at high risk of complications. Expand
Rate of use and effectiveness of oseltamivir in the treatment of influenza illness in high‐risk populations: A systematic review and meta‐analysis
Oseltamivir is recommended in the treatment of influenza illness in high‐risk populations, including those with chronic heart and lung diseases.